SYRE (Spyre Therapeutics, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings
Spyre Therapeutics, Inc. Common Stock (SYRE) is a publicly traded Healthcare sector company. As of May 21, 2026, SYRE trades at $71.70 with a market cap of $6.09B and a P/E ratio of 0.00. SYRE moved +7.99% today. Year to date, SYRE is +140.05%; over the trailing twelve months it is +367.01%. Its 52-week range spans $10.91 to $78.80. Analyst consensus is strong buy with an average price target of $95.86. Rallies surfaces SYRE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Who owns SYRE stock?
Hedge funds tracked by Rallies that own SYRE include Soros Fund. The latest tracked quarter is Mar 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Spyre Therapeutics, Inc. Common Stock.
SYRE Key Metrics
Key financial metrics for SYRE
Metric
Value
Price
$71.70
Market Cap
$6.09B
P/E Ratio
0.00
EPS
$0.00
Dividend Yield
0.00%
52-Week High
$78.80
52-Week Low
$10.91
Volume
628
Avg Volume
0
Revenue (TTM)
$0
Net Income
$-155.20M
Gross Margin
0.00%
Top Hedge Funds Holding SYRE
Soros Fund holds 125.00K shares of SYRE, changed -50.00% as of Mar 31, 2025.
Hedge funds tracked by Rallies that own SYRE include Soros Fund. The latest tracked quarter is Mar 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Spyre Therapeutics, Inc. Common Stock.
Does Rallies show 13F holders for SYRE?
Yes. Rallies tracks hedge fund and 13F ownership data for SYRE, including fund names, share counts, latest tracked quarter, and position changes when available.
Is SYRE research on Rallies investment advice?
No. Rallies provides research, data, and educational context for SYRE. It does not provide personalized investment advice.
